
Senior Principal AI Consultant - Evinova
AstraZeneca21 days ago
Barcelona, SpainStaff+
Responsibilities
- Build sophisticated GenAI, machine learning, optimization, and agentic AI solutions tailored to life sciences.
- Support internal AI development initiatives and client-facing consulting engagements.
- Present AI initiative progress and translate complex technical outcomes into clear business value for senior leadership and stakeholders.
- Gather stakeholder feedback and ensure AI outcomes align with business goals.
- Connect AI capabilities with pharmaceutical requirements across AI, Product, Strategy, and UX.
- Apply critical analysis to deliver measurable digital transformation outcomes.
Requirements
- 5+ years of experience designing novel algorithms and applied AI/ML solutions that drove measurable business impact.
- Experience working for a consultancy on Data/AI initiatives and engaging with clients.
- Experience building GenAI solutions for real-world use cases.
- Solid understanding of agentic AI frameworks such as LangChain, Google GenAI SDK, and LlamaIndex.
- Experience using GenAI coding assistants such as GitHub Copilot and Cursor.
- Expert knowledge of Python and standard packages including pandas and scikit-learn.
- Expertise in data cleaning and processing methodologies.
- Expertise managing business stakeholders in high-stakes contexts.
- Excellent verbal and written communication skills, including presenting technical concepts clearly to non-technical stakeholders.
- Previous life sciences or pharmaceutical industry experience is desirable but not required.
Benefits
- Hybrid working with an average minimum of three days per week in the office, balanced with individual flexibility.
- Inclusive workplace committed to diversity, equality of opportunity, and compliance with applicable employment and work-authorization requirements.
Tech Stack
Categories
About AstraZeneca
AstraZeneca is a global biopharmaceutical company that discovers, develops, manufactures, and commercializes prescription medicines for patients and healthcare systems. Its portfolio spans oncology, cardiovascular, renal and metabolism, respiratory and immunology, and rare diseases (expanded by the 2021 acquisition of Alexion). Founded in 1999 and headquartered in Cambridge, UK, it is a public company listed on the London Stock Exchange and Nasdaq, generating revenue primarily from drug sales and partnerships.